TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34092233
Drug: Rigosertib (RGS)
Normalized name: DNA, D((2'-O-(2-METHOXYETHYL))M5RC-SP-(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-SP-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))RA-SP-T-SP-A-SP-M5C-SP-A-SP-T-SP-T-SP-T-SP-M5C-SP-T-SP-A-SP-(2'-O-(2-METHOXYETHYL))M5RC-(2'-O-(2-METHOXYETHYL))R
DrugBank: Rigosertib (DB12146)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rigosertib (RGS) monotherapy (300 mg/kg)
Study: 34092233
Drug: Rigosertib (RGS)
Normalized name: DNA, D((2'-O-(2-METHOXYETHYL))M5RC-SP-(2'-O-(2-METHOXYETHYL))RA-(2'-O-(2-METHOXYETHYL))RG-SP-(2'-O-(2-METHOXYETHYL))RG-(2'-O-(2-METHOXYETHYL))RA-SP-T-SP-A-SP-M5C-SP-A-SP-T-SP-T-SP-T-SP-M5C-SP-T-SP-A-SP-(2'-O-(2-METHOXYETHYL))M5RC-(2'-O-(2-METHOXYETHYL))R
DrugBank: Rigosertib (DB12146)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rigosertib (RGS) in combination with αPD1 + αCTLA4
Study: 34092549
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of subanesthetic intravenous ketamine and therapist-administered e-CBT over 14 weeks
Study: 34092549
Drug: Waitlist control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Waitlist control group receiving the experimental treatment after 14 weeks
Study: 34093444
Drug: Levothyroxine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levothyroxine treatment (median dose of 50 μg)
Study: 34094549
Drug: Medium and
Normalized name: blood pressure test kit medium and large cuffs MISCELL KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medium and long treatment regimens of low-dose IL-2
Study: 34094549
Drug: Long treatment
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long treatment regimen of low-dose IL-2
Study: 34095161
Drug: Electroacupuncture therapy,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electroacupuncture therapy, details on dosage and duration not available
Study: 34095178
Drug: Multimodal prehabilitation,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal prehabilitation, details on dosage and duration not available
Study: 34096037
Drug: Rectal water-contrast
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rectal water-contrast transvaginal ultrasonography (RWC-TVS)
Study: 34096690
Drug: Sotorasib (960
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sotorasib (960 mg orally once daily)
Study: 34097071
Drug: Dexamethasone-corticotropin-releasing hormone
Normalized name: corticotropin-releasing hormone
DrugBank: Corticorelin (DB05394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone-corticotropin-releasing hormone (Dex/CRH) test
Study: 34097100
Drug: Trifluridine/tipiracil (FTD/TPI)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trifluridine/tipiracil (FTD/TPI) at a dose of 35 mg/m²
Study: 34098895
Drug: K-001 (1350
Approvals — FDA: no, EMA: no, PMDA: no
Description: K-001 (1350 mg to 2160 mg, administered twice daily in four-week cycles)
Study: 34098967
Drug: Patients without
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients without treatment limitation
Study: 34098967
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with any treatment limitation
Study: 34098967
Drug: Treatment limitations
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment limitations (PTL)
Study: 34099518
Drug: Tubeless, on-body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tubeless, on-body automated insulin delivery system with customizable glycemic targets
Study: 34099518
Drug: Usual insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Usual insulin regimen (2-week standard therapy phase)
Study: 34099718
Drug: neoadjuvant eribulin
Approvals — FDA: no, EMA: no, PMDA: no
Description: neoadjuvant eribulin therapy
Study: 34099953
Drug: Manual lymphatic
Normalized name: PINPOINT Lymphatics Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual lymphatic drainage treatment
Study: 34100024
Drug: Virus-targeted treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virus-targeted treatment and prevention strategies
Study: 34101090
Drug: RNA-pulsed dendritic
Approvals — FDA: no, EMA: no, PMDA: no
Description: RNA-pulsed dendritic cell vaccines
Study: 34101090
Drug: RNA-loaded nanoparticle
Approvals — FDA: no, EMA: no, PMDA: no
Description: RNA-loaded nanoparticle vaccines
Study: 34103352
Drug: Durvalumab 1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab 1500 mg given every 4 weeks until progression or unacceptable toxicity (dMMR cohort)
Study: 34103352
Drug: Durvalumab 1500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Durvalumab 1500 mg given every 4 weeks until progression or unacceptable toxicity (pMMR cohort)
Study: 34104849
Drug: Combined EPA+DHA
Normalized name: eicosapentaenoate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined EPA+DHA intake (median daily intake 70 mg, IQR: 32, 145 mg)
Study: 34104878
Drug: Convalescent plasma
Normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convalescent plasma (CP) therapy, transfusion in three doses of 3 mL/kg of recipient body weight at 2-day intervals
Study: 34105312
Drug: Early combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early combination plan (DMARD and biologic started together)
Study: 34105312
Drug: Step-up plan
Normalized name: Plan B One-Step
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Step-up plan (initial nonbiologic DMARD monotherapy)
Study: 34105312
Drug: Biologic first
Normalized name: beremagene geperpavec
DrugBank: Beremagene geperpavec (DB17831)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biologic first plan (biologic monotherapy)
Study: 34105312
Drug: Early combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early combination plan
Study: 34105902
Drug: Inpatient trauma
Normalized name: Impatiens irvingii whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inpatient trauma treatment
Study: 34107166
Drug: Napabucasin (240
Approvals — FDA: no, EMA: no, PMDA: no
Description: Napabucasin (240 mg twice daily; days 1-11)
Study: 34107771
Drug: Allogeneic bone
Normalized name: Human allogeneic bone marrow derived osteoblastic cells
DrugBank: Human allogeneic bone marrow derived osteoblastic cells (DB17890)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allogeneic bone marrow transplant (alloBMT) with continuous antiretroviral therapy
Study: 34107914
Drug: Simulation-based nursing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simulation-based nursing intervention including usual care, an informational booklet from NCI, and three meetings with a nurse interventionist during radiation treatment followed by a booster call two weeks posttreatment.
Study: 34108168
Drug: IA injection
Normalized name: factor VIIa Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: IA injection of triamcinolone acetonide
Study: 34109185
Drug: Pre-operative/Neoadjuvant Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-operative/Neoadjuvant Therapy and Vascular Debranching followed by Resection
Study: 34109306
Drug: C-IVIG (0.15
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-IVIG (0.15 g/kg)
Study: 34109306
Drug: C-IVIG (0.20
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-IVIG (0.20 g/kg)
Study: 34109306
Drug: C-IVIG (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-IVIG (0.25 g/kg)
Study: 34109306
Drug: C-IVIG (0.30
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-IVIG (0.30 g/kg)
Study: 34109306
Drug: C-IVIG (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: C-IVIG (all dosage arms)
Study: 34109484
Drug: FCN-437c 50
Approvals — FDA: no, EMA: no, PMDA: no
Description: FCN-437c 50 mg
Study: 34109484
Drug: FCN-437c 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: FCN-437c 100 mg
Study: 34109484
Drug: FCN-437c 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: FCN-437c 200 mg
Study: 39188943
Drug: FCN-437c 300
Approvals — FDA: no, EMA: no, PMDA: no
Description: FCN-437c 300 mg
Study: 34109484
Drug: FCN-437c 450
Approvals — FDA: no, EMA: no, PMDA: no
Description: FCN-437c 450 mg
Study: 34109484
Drug: FCN-437c (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: FCN-437c (all doses)
Study: 34109515
Drug: WBRT +
Approvals — FDA: no, EMA: no, PMDA: no
Description: WBRT + sorafenib (200 mg daily for 21 days)
Study: 34109624
Drug: HC-1119 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HC-1119 at doses of 40, 80, 160, and 200 mg/day (part A)
Study: 34109624
Drug: HC-1119 at
Normalized name: AT-III
DrugBank: Antithrombin III human (DB11598)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HC-1119 at doses of 80 and 160 mg (part B)
Study: 34110383
Drug: Ibrutinib (420
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibrutinib (420 mg/d for 3 cycles) followed by combination with venetoclax (ramp-up to 400 mg/d for 24 cycles)
Study: 34110489
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for progressive well-differentiated NETs
Study: 34111887
Drug: Prior use
Normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior use of systemic or topical fluorescein
Study: 34112454
Drug: PREDICT-TAVR score
Normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
Approvals — FDA: no, EMA: no, PMDA: no
Description: PREDICT-TAVR score (6-item score including blood hemoglobin, serum iron concentrations, oral anticoagulation, dual antiplatelet therapy, common femoral artery diameter, and creatinine clearance)
Study: 34112707
Drug: Sulindac 150
Normalized name: sulindac 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sulindac 150 mg twice daily for 12 months
Study: 34113254
Drug: Qingre Huoxue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Qingre Huoxue treatment (QRHXD/QRHXEP)
Study: 34113571
Drug: Chemo or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemo or targeted therapy alone
Study: 34115136
Drug: Gene therapy
Normalized name: E1A gene therapy
DrugBank: RGG0853 (DB18669)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gene therapy for SCD with nonmyeloablative conditioning and related haploidentical donors
Study: 34115136
Drug: Gene therapy
Normalized name: E1A gene therapy
DrugBank: RGG0853 (DB18669)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gene therapy for SCD
Study: 34115136
Drug: Busulfan treatment
Normalized name: Busulfan
DrugBank: Busulfan (DB01008)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Busulfan treatment
Study: 34115607
Drug: Surveys administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surveys administered through the Roadmap 2.0 app
Study: 34116329
Drug: ICS (Inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICS (Inhaled Corticosteroids)
Study: 34116329
Drug: LABA +
Normalized name: Labafenogene marselecobac
DrugBank: Labafenogene marselecobac (DB17618)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LABA + ICS (Long-Acting Beta-Agonists + Inhaled Corticosteroids)
Study: 34116329
Drug: LABA +
Normalized name: Labafenogene marselecobac
DrugBank: Labafenogene marselecobac (DB17618)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LABA + LAMA (Long-Acting Beta-Agonists + Long-Acting Muscarinic Antagonists)
Study: 34116329
Drug: LABA +
Normalized name: Labafenogene marselecobac
DrugBank: Labafenogene marselecobac (DB17618)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LABA + LAMA + ICS (Triple therapy)
Study: 34116329
Drug: No medication
Approvals — FDA: no, EMA: no, PMDA: no
Description: No medication (never used ICS, LABA + ICS, LABA + LAMA, or triple therapy)
Study: 34116533
Drug: Capecitabine or
Normalized name: capecitabine Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capecitabine or 5-fluorouracil in combination with oxaliplatin or irinotecan
Study: 34116645
Drug: Oral anti-diabetic
Normalized name: Diabetic Tussin EX Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anti-diabetic therapies
Study: 34116645
Drug: Anti-hypertensive therapies
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anti-hypertensive therapies
Study: 34116645
Drug: Lipid-lowering therapies
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid-lowering therapies
Study: 34116645
Drug: Insulin therapies
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin therapies
Study: 34116645
Drug: HbA1c treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HbA1c treatment target not achieved (HbA1c ≥ 7.0%)
Study: 34116645
Drug: Blood pressure
Normalized name: Blood Pressure Kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blood pressure treatment target not achieved (BP ≥ 140/90 mmHg)
Study: 34116645
Drug: LDL-cholesterol treatment
Normalized name: Cholesterol
DrugBank: Cholesterol (DB04540)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LDL-cholesterol treatment target not achieved (LDL-cholesterol ≥ 2.6 mmol/L)
Study: 34116699
Drug: Availability of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Availability of antidepressants at the clinic
Study: 34116727
Drug: ABLE intervention
Normalized name: ABL
DrugBank: Lauric acid (DB03017)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABLE intervention (8-week home-based occupational therapy program)
Study: 34117077
Drug: Mineralocorticoid Receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mineralocorticoid Receptor Antagonists
Study: 34117380
Drug: 0.2 μg/day fluocinolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 μg/day fluocinolone acetonide implant (FAi)
Study: 34117601
Drug: Physical functional
Normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical functional capacity measured by daily home accelerometry for IPF
Study: 34117737
Drug: i.v. methylprednisolone
Approvals — FDA: no, EMA: no, PMDA: no
Description: i.v. methylprednisolone (500 mg for 3 consecutive days, total of 1500 mg) followed by i.v. Tocilizumab (8 mg/kg) on day 3 and thereafter weekly s.c. Tocilizumab injections (162 mg) over 52 weeks
Study: 34117737
Drug: Glucocorticoid pulse
Normalized name: dulse extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoid pulse therapy
Study: 34117759
Drug: Increased X-
Approvals — FDA: no, EMA: no, PMDA: no
Description: Increased X- and Y-chromosome dosage
Study: 34118018
Drug: Transdermal 2%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal 2% testosterone gel 300 mcg/day (T group)
Study: 34118018
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (T + E group)
Study: 34118198
Drug: Pralsetinib 400
Normalized name: pralsetinib
DrugBank: Pralsetinib (DB15822)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Pralsetinib 400 mg once-daily oral treatment
Study: 34118361
Drug: AWRK6 synthetic
Normalized name: Camphor (synthetic)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AWRK6 synthetic peptide via intraperitoneal injection
Study: 34118361
Drug: AWRK6 synthetic
Normalized name: Camphor (synthetic)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AWRK6 synthetic peptide in insulin-induced HepG2 cells
Study: 34118856
Drug: Care of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Care of the Dying Evaluation - Emergency Medicine questionnaire
Study: 34118944
Drug: Chloroquine (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chloroquine (750 mg)
Study: 34120214
Drug: Autologous antigen-specific
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous antigen-specific T-cells (Melan-A and MELOE-1) with subcutaneous IL-2
Study: 34120312
Drug: Gefitinib 250
Normalized name: gefitinib 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gefitinib 250 mg QD
Study: 34122611
Drug: Traditional Chinese
Normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Traditional Chinese Medicine
Study: 39739907
Drug: Nilotinib 300
Normalized name: Nilotinib
DrugBank: Nilotinib (DB04868)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Nilotinib 300 mg twice-daily
Study: 38104036
Drug: Treatment-free remission
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment-free remission (TFR)
Study: 34124106
Drug: Sleep-disordered breathing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sleep-disordered breathing treatment, specific intervention details not available
Study: 34124111
Drug: Patient-Controlled Intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-Controlled Intravenous Analgesia with Tramadol
Study: 34124781
Drug: Nephrotoxic serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nephrotoxic serum (NTS) administered on day 14 after EAV induction.
Study: 34124781
Drug: Small molecule
Normalized name: Small molecule melanocortin 4 receptor agonist
DrugBank: LB54640 (DB18331)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Small molecule kinase inhibitor (fostamatinib) administered over a 4-day treatment period.
Study: 34124781
Drug: Control protein
Normalized name: protein C
DrugBank: Protein C (DB11312)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control protein (not MPO) administered instead of MPO.
Study: 34125405
Drug: Glecaprevir/pibrentasvir (8-week
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glecaprevir/pibrentasvir (8-week treatment)
Study: 34126109
Drug: ALXN1830 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: ALXN1830 (10 mg/kg) administered as five weekly intravenous doses
Study: 34126262
Drug: PF-06480605 (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-06480605 (500 mg intravenous every 2 weeks, 7 doses total)
Study: 34126756
Drug: Cardioprotective medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cardioprotective medications
Study: 34126939
Drug: TAF (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAF (25 mg/d)
Study: 34126939
Drug: TDF (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDF (300 mg/d)
Study: 34126939
Drug: ETV (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: ETV (0.5 mg/d)
Study: 34129158
Drug: Adipose tissue-derived
Normalized name: human adipose preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adipose tissue-derived mesenchymal stem/stromal cells (ADSC) infusion at a dosage of 1 million cells/kg of body weight via intravenous route.
Study: 34129808
Drug: Corticosteroid treatment,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroid treatment, specific dosage and duration not available
Study: 34722661
Drug: Control group,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group, specific treatment not available
Study: 34130554
Drug: Solution-Focused Brief
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Solution-Focused Brief Therapy
Study: 34130709
Drug: Oral nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral nutritional supplements (ONS) with nutritional counseling
Study: 34130731
Drug: Early combination
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Early combination (EC) therapy
Study: 34130731
Drug: Metformin monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin monotherapy (MET)
Study: 34131041
Drug: Olaparib in
Normalized name: Product containing olaparib in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olaparib in combination with weekly carboplatin plus paclitaxel
Study: 34131423
Drug: TAK-003 (tetravalent
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAK-003 (tetravalent dengue vaccine)
Study: 34131821
Drug: HIPEC with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIPEC with gemcitabine administered at 1000 mg/m²
Study: 34132071
Drug: Intravenous administration
Normalized name: intravenous administration set
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous administration of high-dose selenium (2,000 μg/day)
Study: 34132642
Drug: Directly Observed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Directly Observed Therapy (DOT) via mobile health application carried out by community workers.
Study: 34133209
Drug: Germline genotype-directed
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Germline genotype-directed therapy
Study: 34134507
Drug: Hypotension during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypotension during endovascular therapy in patients with no PComA
Study: 34134507
Drug: Hypotension during
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hypotension during endovascular therapy in patients with PComA
Study: 34134830
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBGT)
Study: 34134832
Drug: Memory Support
Normalized name: Brainstrong Memory Support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Memory Support Treatment Provider Checklist
Study: 34135022
Drug: Net endogenous
Normalized name: [(im-Bzl)-D-His6,Pro9-NEt]-gonadotropin releasing hormone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Net endogenous acid production using urinary excretion
Study: 34135566
Drug: Intravitreal injection
Normalized name: Eylea 2 MG per 0.05 ML Intravitreal Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravitreal injection guide (IIG)
Study: 34135843
Drug: Repeated Mesenchymal
Normalized name: eicosyl povidone (2 eicosyl branches-repeat)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Repeated Mesenchymal Stem Cell Injections
Study: 34136501
Drug: Liraglutide, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Liraglutide, a glucagon-like peptide-1 receptor agonist
Study: 34136782
Drug: Patiromer at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patiromer at doses ranging from 4.2 to 16.8 g twice daily
Study: 34136987
Drug: MT-8 h
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: MT-8 h and MT-12 h formulations (120 mg)
Study: 34136987
Drug: MT-12 h
Normalized name: lipase
Approvals — FDA: no, EMA: no, PMDA: no
Description: MT-12 h once-daily for 3 days at three dose levels
Study: 34136987
Drug: MM-12 h
Approvals — FDA: no, EMA: no, PMDA: no
Description: MM-12 h formulation at two dose levels
Study: 34136987
Drug: Immediate release
Normalized name: Namenda, immediate release oral kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate release (IR) formulation (120 mg)
Study: 34137430
Drug: Vedolizumab 300
Normalized name: vedolizumab 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vedolizumab 300 mg every 8 weeks